Cargando…

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma

BACKGROUND: The fibroblast growth factor receptor 4 (FGFR4) pathway is an essential regulatory component of bile acid synthesis, and its relationship with hepatocellular carcinoma (HCC) has been reported. We investigated the gene expression and clinical significance of FGFR4 and related pathways in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Changhoon, Kang, Jihoon, Kim, Deokhoon, Kim, Kyu-Pyo, Ryoo, Baek-Yeol, Hong, Seung-Mo, Hwang, Jung Jin, Jeong, Seong-Yun, Hwang, Shin, Kim, Ki-Hun, Lee, Young-Joo, Hoeflich, Klaus P., Schmidt-Kittler, Oleg, Miller, Stephen, Choi, Eun Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503556/ https://www.ncbi.nlm.nih.gov/pubmed/28445152 http://dx.doi.org/10.18632/oncotarget.16951

Ejemplares similares

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2023)

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Effect of age on the prognosis of intrahepatic cholangiocarcinoma
por: Kim, Jung Hun, et al.
Publicado: (2023)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
por: Zhang, Lei, et al.
Publicado: (2023)

The role of FGFR inhibitors in the treatment of intrahepatic cholangiocarcinoma—unveiling the future challenges in drug therapy
por: Nishida, Naoshi
Publicado: (2023)

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
por: Yoo, Changhoon, et al.
Publicado: (2019)

A Case of Clonorchiasis with Focal Intrahepatic Duct Dilatation Mimicking an Intrahepatic Cholangiocarcinoma
por: Kim, Bong Gap, et al.
Publicado: (2011)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
por: Salati, Massimiliano, et al.
Publicado: (2021)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Real-world data analysis of patients with cancer of unknown primary
por: Kang, Sora, et al.
Publicado: (2021)

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only
por: Shin, Su-Jin, et al.
Publicado: (2018)

Erratum to: Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
por: Tsujie, Masanori, et al.
Publicado: (2021)

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies
por: Lidsky, Michael E., et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

ALPPS in a patient with periductal infiltrating intrahepatic cholangiocarcinoma
por: Ha, Sumin, et al.
Publicado: (2017)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
por: Yoo, Changhoon, et al.
Publicado: (2018)

Intrahepatic cholangiocarcinoma arising in Caroli's disease
por: Jang, Min Hye, et al.
Publicado: (2014)

Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing FGFR2 signalling
por: Xu, Yun‐Fei, et al.
Publicado: (2018)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
por: Peng, Min, et al.
Publicado: (2023)

Complex Liver Resections for Intrahepatic Cholangiocarcinoma
por: Reese, Tim, et al.
Publicado: (2021)

Novel Preoperative Nomogram for Prediction of Futile Resection in Patients Undergoing Exploration for Potentially Resectable Intrahepatic Cholangiocarcinoma
por: Nam, Kwangwoo, et al.
Publicado: (2017)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
por: Yoo, Changhoon, et al.
Publicado: (2021)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Postoperative CA19-9 Change Is a Useful Predictor of Intrahepatic Cholangiocarcinoma Survival following Liver Resection
por: Yoo, Tae, et al.
Publicado: (2015)

Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years
por: Kim, Dong Kyun, et al.
Publicado: (2019)

Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations
por: Kim, Young-Ho, et al.
Publicado: (2016)

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
por: Borad, Mitesh J., et al.
Publicado: (2014)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oqsgoa5rvqc9gc13t5i3bjtfgr